Myriad Genetics: The Streak of Missing Estimates Puts Management Credibility on the Line

Myriad Genetics Inc (MYGN) reports second-quarter fiscal 2026 earnings after the close on July 30, 2026, with analysts expecting a loss of $0.08 per share. The molecular diagnostics company faces a critical test as it attempts to reverse a pattern of inconsistent profitability while navigating a challenging operating environment. With the stock trading at $5.05 and analyst sentiment mixed, investors will be watching closely for signs of sustainable improvement in the company's core genetic testing business.

Part 1: Earnings Preview

Myriad Genetics is a molecular diagnostic company specializing in genetic testing and precision medicine, with a focus on oncology, women's health, and mental health applications. The company's revenue streams include hereditary cancer testing, tumor profiling, and pharmacogenomics products that help guide treatment decisions.

Myriad reports Q2 fiscal 2026 results after the close on July 30, 2026. The consensus estimate calls for a loss of $0.08 per share, with revenue expected at approximately $206.03 million. Last quarter, the company reported a loss of $0.16 per share for Q1 fiscal 2026, meeting analyst expectations but representing a significant deterioration from the prior year. Year-over-year, the comparison is challenging — the company is expected to swing from a loss of $0.06 per share in Q2 fiscal 2025 to a wider loss of $0.08 per share, representing -33.33% growth.

Three key themes define this earnings story:

Profitability Trajectory: After posting a surprising profit of $0.02 per share in Q4 fiscal 2025, Myriad has struggled to maintain momentum, with Q1 showing a significant loss. Investors will scrutinize whether the company can stabilize its bottom line or if profitability remains elusive.

Revenue Growth Sustainability: Historical data shows Myriad has topped consensus revenue estimates in three of the last four quarters, including a 5.55% beat in Q2 fiscal 2025. The question is whether the company can continue expanding its testing volumes and pricing power in an increasingly competitive genetic testing market.

Operational Efficiency: With estimates calling for continued losses in the near term before a potential return to profitability in Q3, management's commentary on cost controls, reimbursement trends, and operational leverage will be critical to the investment thesis.

Analyst commentary ahead of the release has been cautious. The consensus has actually revised estimates lower, with the prior estimate for Q2 at a loss of $0.06 per share now standing at $0.08. However, looking ahead, analysts project a sharp improvement to a profit of $0.03 per share in Q3 fiscal 2026, suggesting expectations for a meaningful inflection point in the business.

Part 2: Historical Earnings Performance

Myriad Genetics has demonstrated a mixed but recently improving track record on earnings surprises. Over the past four quarters, the company has beaten or met consensus estimates three times, showing some ability to manage expectations.

The pattern reveals significant volatility in execution. In Q2 fiscal 2025, Myriad posted a loss of $0.06 per share against expectations of $0.11, delivering a +45.45% surprise. The following quarter saw a miss, with a loss of $0.13 versus the $0.11 estimate, a -18.18% surprise. Q4 fiscal 2025 marked a turning point with a profit of $0.02 per share against expectations of a $0.11 loss — a dramatic +118.18% surprise that suggested potential operational momentum. However, Q1 fiscal 2026 brought investors back to earth, with the company reporting a loss of $0.16 per share exactly in line with estimates.

The trend suggests a company in transition, capable of significant upside surprises but lacking consistent profitability. The dramatic Q4 beat followed by Q1's return to losses raises questions about whether Myriad can establish a sustainable path to profitability or if results will remain choppy.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Myriad Genetics typically reports earnings after market close, meaning Day 0 captures anticipatory moves before results are released, while Day +1 reflects the market's first full session to digest the actual numbers.

Historical price action around Myriad's earnings releases shows extreme volatility, particularly in the sessions following results. The average absolute Day 0 move of 2.30% is relatively modest, with an average range of 5.83%, suggesting limited pre-announcement positioning. However, Day +1 tells a dramatically different story, with an average absolute move of 18.01% and an average range of 18.38% — indicating that the market's reaction to actual results tends to be severe.

Recent history highlights this pattern. Following the May 2026 report, the stock initially rose 1.82% on Day 0 but then plunged 18.29% on Day +1. The August 2025 report saw a modest 2.76% decline on Day 0 followed by a massive 46.51% surge on Day +1 after the company beat estimates. The May 2025 report was particularly brutal, with the stock falling 5.58% on Day 0 and then collapsing 41.27% on Day +1.

This pattern suggests investors should brace for significant volatility, with the real price discovery occurring in the session after results are released. The magnitude of historical moves indicates that even small beats or misses can trigger outsized reactions.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 11.97% (±$0.60) for the August 21, 2026 expiration, which is substantially lower than the 18.01% average absolute Day +1 move observed in recent earnings reports. This suggests the options market may be underpricing the potential volatility, presenting possible opportunities for traders expecting a larger-than-usual reaction to the results.

Part 3: What Analysts Are Saying

Analyst sentiment on Myriad Genetics remains cautious, with a consensus rating of 3.20 (between Hold and Buy) based on 10 analysts covering the stock. The breakdown shows 2 Strong Buys, 6 Holds, and 2 Moderate Sells, reflecting a divided Street with no clear conviction in either direction.

The average price target of $6.33 implies approximately 25% upside from the current price of $5.05, with estimates ranging from a low of $4.00 to a high of $10.00. This wide range underscores the uncertainty around Myriad's prospects, with bulls seeing potential for significant appreciation if the company can execute on its turnaround, while bears remain skeptical about the path to sustainable profitability.

Analyst sentiment has remained unchanged over the past month, with no shifts in the rating distribution or average recommendation. This stability suggests the Street is in wait-and-see mode ahead of the Q2 report, with no new catalysts or information prompting revisions to views. The lack of recent upgrades or downgrades indicates analysts are looking for the upcoming earnings release to provide clarity on whether Myriad can deliver on its improvement narrative or if challenges persist.

Part 4: Technical Picture

Myriad Genetics enters earnings with a deteriorating technical picture. The Barchart Technical Opinion has shifted from a Buy signal at 24% one week ago to a Hold signal at 0% currently, indicating a rapid loss of momentum. One month ago, the signal also stood at Buy (24%), highlighting how recent weakness has eroded the technical setup.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal suggests some near-term support, though conviction is limited
• Medium-term (Hold): Neutral reading indicates consolidation and lack of clear directional bias in the intermediate timeframe
• Long-term (50% Sell): Moderate sell signal reflects underlying weakness in the longer-term trend structure

Trend Characteristics: The bearish direction heading into earnings suggests the stock is under technical pressure, with sellers maintaining control of the broader trend.

The stock's position relative to key moving averages paints a mixed picture. At $5.05, MYGN trades below its 5-day ($5.43), 10-day ($5.70), and 20-day ($5.84) moving averages, confirming recent weakness and downward momentum. However, the stock remains above its 50-day ($5.02) and 100-day ($4.83) moving averages, indicating some intermediate-term support. The current price sits below the critical 200-day moving average of $5.63, a bearish signal for the long-term trend.

Key resistance now sits at the 5-day moving average around $5.43, with more significant overhead at the 20-day average of $5.84. Support appears at the 50-day moving average of $5.02, which has provided a floor in recent trading. The technical setup heading into earnings is cautionary — the stock has lost short-term momentum, trades below most near-term moving averages, and shows a bearish longer-term trend. Combined with the extreme historical volatility around earnings releases, the technical picture suggests elevated risk for shareholders holding through the announcement, with limited technical support if results disappoint.